Metabolic, toxicological, and safety considerations for drugs used to treat ADHD

@article{Duong2012MetabolicTA,
  title={Metabolic, toxicological, and safety considerations for drugs used to treat ADHD},
  author={Sophie Duong and K. Chung and S. Wigal},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2012},
  volume={8},
  pages={543 - 552}
}
Introduction: Pharmacotherapy is frequently used to treat symptoms of attention-deficit/hyperactivity disorder (ADHD), the most common neurobehavioral disorder of childhood. The typically prescribed agents for ADHD have varying durations of effect and degrees of efficacy. The broad range of pharmacological treatments available allows for both single and combination therapies for achieving optimal therapeutic effects. Metabolic, toxicological, and safety information are critical for an informed… Expand
An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations
TLDR
Since there are no reliable biomarkers that can predict individualized response to long-acting stimulants, clinicians need to consider their distinctive pharmacokinetic properties, including the pharmacokinetics profile, rate and extent of absorption, variability, dose proportionality, bioequivalence and potential for accumulation. Expand
Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report
TLDR
In this case, cooperation between the medical team and the patients’ relatives was key to successful treatment and pharmacogenetic testing should be included in the management plan for ADHD. Expand
Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage
TLDR
Weight is a reliable clinical parameter for optimal dose titration in patients with well-adjusted MPH treatment for ADHD and might be used for individual dose optimization and for monitoring of the prescribed dose. Expand
The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities
  • S. Faraone
  • Medicine
  • Neuroscience & Biobehavioral Reviews
  • 2018
TLDR
This review aims to educate physicians regarding differences in pharmacology and mechanisms of action between amphetamine and methylphenidate, thus enhancing physician understanding of psychostimulants and their use in managing individuals with ADHD who may have comorbid psychiatric conditions. Expand
[Prescription of methylphenidate for children: importance of recommendations to limit misuse].
TLDR
Whether the recommendations on methylphenidate use for children are being respected, the extent of problematic use ofethylphenidate, and the impact of said recommendations being respected on the development of problematic consumption are assessed. Expand
Pharmacological treatment of adult ADHD
TLDR
Effect sizes from the most recent studies are calculated and they are almost identical with prior estimates, and in terms of Cohen-d typically indicate medium-to-high effect sizes for the pharmacotherapy of adult ADHD. Expand
Psychostimulants and brain dysfunction: A review of the relevant neurotoxic effects
Psychostimulants abuse is a major public concern because is associated with serious health complications, including devastating consequences on the central nervous system (CNS). The neurotoxicExpand
Preclinical pharmacology of amphetamine: implications for the treatment of neuropsychiatric disorders.
TLDR
Preclinical evidence suggesting that direct interactions of amphetamine with monoamine systems, which results in increased synaptic monoamine availability, has downstream effects on nonmonoaminergic systems, including glutamate, endogenous opioid, endocannabinoid, and acetylcholine systems are described. Expand
Striatal volume deficits in children with ADHD who present a poor response to methylphenidate
TLDR
The hypothesis of the involvement of the caudate and accumbens nuclei in MPH response and in ADHD pathophysiology is supported. Expand
Methylphenidate Hydrochloride Modified-Release in Adults with Attention Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo- Controlled Trial
Introduction: Treatment options for adults with attention deficit hyperactivity disorder (ADHD) are limited. The study was conducted to confirm the clinically effective and safe dose ofExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 86 REFERENCES
Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.
TLDR
This review summarizes the recent advances in ADHD treatment, providing advantages, disadvantages, and clinical pearls for the use of stimulant and nonstimulant medications. Expand
Non–stimulant medications in the treatment of ADHD
TLDR
A large and still increasing body of data supports the usefulness of atomoxetine, a once daily dosing, and new selective noradrenalin reuptake inhibitor, with few side effects. Expand
Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults
  • S. Wigal
  • Psychology, Medicine
  • CNS Drugs
  • 2009
TLDR
Evaluating the efficacy and safety profiles of medications used for the management of ADHD suggests that the combination of behavioural and medical therapy may benefit most patients, and future research may provide an improved understanding of polypharmacy. Expand
Methylphenidate and μ opioid receptor interactions: A pharmacological target for prevention of stimulant abuse
TLDR
The MOPR is identified as a potential target for attenuating rewarding effects of methylphenidate and a formulation that combines naltrexone with MPH could be a useful pharmaceutical approach to alleviate abuse potential of MPH and other stimulants. Expand
Guanfacine and guanfacine extended release: treatment for ADHD and related disorders.
TLDR
Guanfacine extended release (GXR), a once-daily formulation has been manufactured and studied in phase III clinical trials and appears to be efficacious in improving ADHD in children, and would be the first alpha(2A) adrenoceptor agonist marketed for ADHD. Expand
Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders
TLDR
Clonidine and clonidine extended-release could be efficacious and safe for the treatment of ADHD both as monotherapy and as adjunctive therapy with stimulant medications in selected patients. Expand
Once-daily treatment of ADHD with guanfacine: patient implications
  • B. Strange
  • Medicine
  • Neuropsychiatric disease and treatment
  • 2008
TLDR
The preliminary data for guanfacine extended release and its effectiveness in decreasing the symptoms of ADHD are introduced and the current literature on the effectiveness of guanFacine in treating ADHD is reviewed. Expand
Clonidine Extended-Release Tablets as Add-on Therapy to Psychostimulants in Children and Adolescents With ADHD
TLDR
The results of this study suggest that CLON-XR in combination with stimulants is useful in reducing ADHD in children and adolescents with partial response to stimulants. Expand
The Role of Alpha2-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder
TLDR
This review will encompass the clinical study database for novel formulations of alpha2-adrenergic agonists, enabling the reader to appreciate their place in ADHD treatment as well as the potential utility of a combination approach with psychostimulants for patients with complex ADHD. Expand
Advances in the Pharmacotherapy of Attention‐Deficit‐Hyperactivity Disorder: Focus on Methylphenidate Formulations
The psychostimulant dl‐methylphenidate (MPH) remains the most common drug therapy in child and adolescent psychiatry for the treatment of attention‐deficit‐hyperactivity disorder (ADHD). Evidence ofExpand
...
1
2
3
4
5
...